Herantis Pharma Plc
Press release 20 Dec 2022 at 1:00 p.m. EET
Save the date: Virtual R&D update webinar January 19, 2023 (14:00-15:00 EET/13:00-14:00 CET)
Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease-modifying therapies for Parkinson’s disease, will host a virtual R&D update webinar on Thursday January 19th, 2023, for investors, analysts, media and for anyone interested in Herantis and our HER-096 program for Parkinson’s disease.
The agenda and details of how to join the meeting will be available in a press release and on the Company’s website (www.herantis.com), which will be issued closer to the event.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com